lncRNA PCAT14对甲状腺癌细胞侵袭转移的影响
Effects of lncRNA PCAT14 on Invasion and Metastasis of Thyroid Cancer Cells
DOI: 10.12677/ACM.2021.116415, PDF,   
作者: 宋烨梅, 华 慧, 李晓琴:山东第一医科大学(山东省医学科学院),山东省肿瘤防治研究院(山东省肿瘤医院)中心实验室,山东 济南
关键词: 甲状腺癌lncRNA PCAT14侵袭转移Thyroid Cancer lncRNA PCAT14 Invasion Metastasis
摘要: 目的:探讨lncRNA PCAT14对甲状腺癌细胞增殖和侵袭的影响及其分子机制。方法:生物信息学方法预测lncRNA PCAT14表达与肾癌患者临床分期的相关性。选择TPC-1甲状腺癌细胞系转染,分别将PCAT14质粒(实验组)或空载对照质粒(对照组)转至甲状腺癌细胞中。使用qPCR检测PCAT14质粒转染效率。细胞计数实验及克隆形成实验检测转染后细胞增殖活性,Transwell侵袭实验检测转染后甲状腺细胞的侵袭能力。Western blot检测EMT相关标记物的蛋白表达水平。生物信息学方法预测lncRNA PCAT14可能结合的蛋白。结果:TCGA数据库显示,甲状腺癌组织lncRNA PCAT14相对表达水平显著低于癌旁正常组织(P < 0.05)。lncRNA PCAT14在甲状腺癌晚期患者肿瘤组织中相对表达量更低(P < 0.01)。与对照组比较,实验组lncRNA PCAT14相对表达水平显著升高(P < 0.05),细胞增殖活性(P < 0.05)和细胞的侵袭能力显著降低(P < 0.01)。同时,实验组lncRNA PCAT14过表达抑制了EMT相关蛋白的表达。lncRNA PCAT14可能与DBX2结合发挥生物学功能。结论:lncRNA PCAT14在甲状腺癌组织中低表达,与肾癌患者临床分期相关。过表达lncRNA PCAT14可明显抑制肾癌细胞增殖和侵袭,其分子机制可能为lncRNA PCAT14与DBX2结合发挥生物学功能。
Abstract: Objective: To investigate the effect of lncRNA PCAT14 on the invasion and metastasis of thyroid cancer cells and its molecular mechanism. Methods: Bioinformatics methods predict the correlation between the expression of lncRNA PCAT14 and the clinical stage of renal cancer patients. Select TPC-1 thyroid cancer cell line for transfection, and transfer PCAT14 plasmid (experimental group) or empty control plasmid (control group) to thyroid cancer cells respectively. QPCR was used to detect the transfection efficiency of PCAT14 plasmid. Cell counting experiment and clone formation experiment were used to detect cell proliferation activity after transfection, and Transwell invasion experiment was used to detect the invasion ability of thyroid cells after transfection. Western blot was used to detect the protein expression level of EMT-related markers. Bioinformatics methods predict the protein that lncRNA PCAT14 may bind. Results: The TCGA database showed that the relative expression level of lncRNA PCAT14 in thyroid cancer tissues was significantly lower than that in normal tissues adjacent to cancer (P < 0.05). The relative expression of lncRNA PCAT14 is lower in the cancer tissues of patients with advanced thyroid cancer (P < 0.01). Compared with the control group, the relative expression level of lncRNA PCAT14 of the experimental group was significantly increased (P < 0.05), and the cell proliferation activity (P < 0.05) and cell invasion ability were significantly reduced (P < 0.01). At the same time, the lncRNA PCAT14 overexpression in the experimental group inhibited the expression of EMT-related proteins. lncRNA PCAT14 may combine with DBX2 to exert biological functions. Conclusion: lncRNA PCAT14 is lowly expressed in thyroid cancer tissues and is related to the clinical stage of renal cancer patients. Overexpression of lncRNA PCAT14 can significantly inhibit the proliferation and invasion of renal cancer cells. The molecular mechanism may be that lncRNA PCAT14 combine with DBX2 to exert biological functions.
文章引用:宋烨梅, 华慧, 李晓琴. lncRNA PCAT14对甲状腺癌细胞侵袭转移的影响[J]. 临床医学进展, 2021, 11(6): 2857-2865. https://doi.org/10.12677/ACM.2021.116415

参考文献

[1] Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74-108. [Google Scholar] [CrossRef] [PubMed]
[2] Gharib, H., Papini, E., Paschke, R., Duick, D.S., Valcavi, R., Hegedus, L., et al. (2010) American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Journal of Endocrinological Investigation, 33, 287-291. [Google Scholar] [CrossRef
[3] Akkas, B.E., Demirel, B.B. and Vural, G.U. (2014) Prognostic Factors Affecting Disease-Specific Survival in Patients with Recurrent and/or Metastatic Differentiated Thyroid Carcinoma Detected by Positron Emission Tomography/Computed Tomography. Thyroid, 24, 287-295. [Google Scholar] [CrossRef] [PubMed]
[4] Kitahara, C.M. and Sosa, J.A. (2016) The Changing Incidence of Thyroid Cancer. Nature Reviews Endocrinology, 12, 646-653. [Google Scholar] [CrossRef] [PubMed]
[5] Cabanillas, M.E., McFadden, D.G. and Durante, C. (2016) Thyroid Cancer. Lancet, 388, 2783-2795. [Google Scholar] [CrossRef
[6] Fagin, J.A. and Wells Jr., S.A. (2016) Biologic and Clinical Perspectives on Thyroid Cancer. The New England Journal of Medicine, 375, 1054-1067. [Google Scholar] [CrossRef
[7] Regalbuto, C., Frasca, F., Pellegriti, G., Malandrino, P., Marturano, I., Di Carlo, I., et al. (2012) Update on Thyroid Cancer Treatment. Future Oncology, 8, 1331-1348. [Google Scholar] [CrossRef] [PubMed]
[8] Blomberg, M., Feldt-Rasmussen, U., Andersen, K.K. and Kjaer, S.K. (2012) Thyroid Cancer in Denmark 1943-2008, before and after Iodine Supplementation. International Journal of Cancer, 131, 2360-2366. [Google Scholar] [CrossRef] [PubMed]
[9] Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., et al. (2009) Chromatin Signature Reveals over a Thousand Highly Conserved Large Non-Coding RNAs in Mammals. Nature, 458, 223-227. [Google Scholar] [CrossRef] [PubMed]
[10] Gong, J., Li, Y., Liu, C.J., Xiang, Y., Li, C., Ye, Y., et al. (2017) A Pan-Cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. Cell Reports, 21, 1968-1981. [Google Scholar] [CrossRef] [PubMed]
[11] Rupaimoole, R., Calin, G.A., Lopez-Berestein, G. and Sood, A.K. (2016) miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 6, 235-246. [Google Scholar] [CrossRef
[12] Esteller, M. (2011) Non-Coding RNAs in Human Disease. Nature Reviews Genetics, 12, 861-874. [Google Scholar] [CrossRef] [PubMed]
[13] White, N.M., Zhao, S.G., Zhang, J., Rozycki, E.B., Dang, H.X., McFadden, S.D., et al. (2017) Multi-Institutional Analysis Shows That Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. European Urology, 71, 257-266. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, Y., Hu, Y., Wu, G., Yang, Y., Tang, Y., Zhang, W., et al. (2017) Long Noncoding RNA PCAT-14 Induces Proliferation and Invasion by Hepatocellular Carcinoma Cells by Inducing Methylation of miR-372. Oncotarget, 8, 34429-34441. [Google Scholar] [CrossRef] [PubMed]
[15] Song, E., Jeon, M.J., Oh, H.S., Han, M., Lee, Y.M., Kim, T.Y., et al. (2018) Do Aggressive Variants of Papillary Thyroid Carcinoma Have Worse Clinical Outcome than Classic Papillary Thyroid Carcinoma? European Journal of Endocrinology, 179, 135-142. [Google Scholar] [CrossRef
[16] Jiang, C., Cheng, T., Zheng, X., Hong, S., Liu, S., Liu, J., et al. (2018) Clinical Behaviors of Rare Variants of Papillary Thyroid Carcinoma Are Associated with Survival: A Population-Level Analysis. Cancer Management and Research, 10, 465-472. [Google Scholar] [CrossRef
[17] Vuong, H.G., Long, N.P., Anh, N.H., Nghi, T.D., Hieu, M.V., Hung, L.P., et al. (2018) Papillary Thyroid Carcinoma with Tall Cell Features Is as Aggressive as Tall Cell Variant: A Meta-Analysis. Endocrine Connections, 7, R286-R293. [Google Scholar] [CrossRef
[18] Nixon, I.J., Simo, R., Newbold, K., Rinaldo, A., Suarez, C., Kowalski, L.P., et al. (2016) Management of Invasive Differentiated Thyroid Cancer. Thyroid, 26, 1156-1166. [Google Scholar] [CrossRef] [PubMed]
[19] Stuelten, C.H., Parent, C.A. and Montell, D.J. (2018) Cell Motility in Cancer Invasion and Metastasis: Insights from Simple Model Organisms. Nature Reviews Cancer, 18, 296-312. [Google Scholar] [CrossRef] [PubMed]
[20] Richards, E.J., Zhang, G., Li, Z.P., Permuth-Wey, J., Challa, S., Li, Y., et al. (2015) Long non-coding RNAs (LncRNA) Regulated by Transforming Growth Factor (TGF) β: LncRNA-Hit-Mediated TGFβ-Induced Epithelial to Mesenchymal Transition in Mammary Epithelia. The Journal of Biological Chemistry, 290, 6857-6867. [Google Scholar] [CrossRef
[21] Braun, J., Hoang-Vu, C., Dralle, H. and Huttelmaier, S. (2010) Down-Regulation of MicroRNAs Directs the EMT and Invasive Potential of Anaplastic Thyroid Carcinomas. Oncogene, 29, 4237-4244. [Google Scholar] [CrossRef] [PubMed]
[22] Shukla, S., Zhang, X., Niknafs, Y.S., Xiao, L., Mehra, R., Cieslik, M., et al. (2016) Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia, 18, 489-499. [Google Scholar] [CrossRef] [PubMed]